4.8 Article

Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine

Journal

THERANOSTICS
Volume 5, Issue 1, Pages 23-42

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/thno.10202

Keywords

aptamer; cancer therapy; active targeting; cancer stem cell; chemoresistance; cancer theranostic

Funding

  1. Australian Research Council [DP140100002]
  2. CASS Foundation
  3. Australia-India Strategic Research Fund
  4. Deakin University Postgraduate Research Scholarship

Ask authors/readers for more resources

Conventional anticancer therapies, such as chemo- and/or radio-therapy are often unable to completely eradicate cancers due to abnormal tumor microenvironment, as well as increased drug/radiation resistance. More effective therapeutic strategies for overcoming these obstacles are urgently in demand. Aptamers, as chemical antibodies that bind to targets with high affinity and specificity, are a promising new and novel agent for both cancer diagnostic and therapeutic applications. Aptamer-based cancer cell targeting facilitates the development of active targeting in which aptamer-mediated drug delivery could provide promising anticancer outcomes. This review is to update the current progress of aptamer-based cancer diagnosis and aptamer-mediated active targeting for cancer therapy in vivo, exploring the potential of this novel form of targeted cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available